Corrigendum to ‘Comparison of the PK, PD, safety, tolerability, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in healthy Japanese males: a phase 1, randomised, crossover study’ [EULAR Rheumatology Open 1 (2025) 282–290]

EULAR Rheumatology Open · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles